Bromantane and MK-2866 Interaction: Avoid | Peptide Database

The 2019 Isenmann et al. study at Freie Universitat Berlin demonstrated that ecdysterone supplementation (administered as spinach extract standardized to ecdysterone content) produced significantly greater increases in lean muscle mass compared to placebo over 10 weeks of resistance training in young, trained men. The highest-dose group gained approximately 2 kg more lean mass than placebo. These results, combined with earlier Soviet-era research and multiple animal studies, support ecdysterone as a meaningful natural anabolic agent. Participants in the Berlin study also showed greater improvements in one-repetition maximum bench press compared to placebo. Animal studies have demonstrated improved grip strength, endurance capacity, and force production with ecdysterone administration. The mechanism likely involves both increased muscle protein synthesis and improved calcium handling within muscle fibers, enhancing contractile efficiency. Preclinical evidence suggests ecdysterone accelerates recovery from exercise-induced muscle damage through anti-inflammatory effects and enhanced protein synthesis rates. Users frequently report reduced delayed-onset muscle soreness (DOMS) and improved training frequency tolerance. However, dedicated human recovery studies are limited. By promoting lean mass accretion without androgenic hormonal disruption, ecdysterone may support body recomposition (simultaneous fat loss and muscle gain) particularly in trained individuals on a structured nutrition plan. Some animal data suggest mild lipolytic effects, though this has not been convincingly demonstrated in human trials.

Join others researching Doxepin — share findings, ask questions, and learn from real experiences Doxepin is a tricyclic compound with a remarkably dose-dependent pharmacological profile. At higher doses (75-300 mg), it functions as a traditional tricyclic antidepressant (TCA) with activity across multiple neurotransmitter systems. However, at ultra-low doses (3-6 mg), doxepin acts almost exclusively as a highly selective histamine H1 receptor antagonist, making it one of the most targeted sleep maintenance agents available. This ultra-low dose formulation was approved by the FDA in 2010 under the brand name Silenor specifically for the treatment of insomnia characterized by difficulty with sleep maintenance. The distinction between high-dose and ultra-low dose doxepin is critical: at 3-6 mg, the drug avoids the anticholinergic, noradrenergic, and serotonergic side effects that characterize tricyclic antidepressants, resulting in a remarkably clean side effect profile. For biohackers and those seeking a non-habit-forming sleep aid, ultra-low dose doxepin offers a compelling option -- it does not produce dependence, does not cause rebound insomnia upon discontinuation, and maintains efficacy with long-term use. Unlike benzodiazepines and Z-drugs, it carries no abuse potential and is not a scheduled substance. At ultra-low doses (3-6 mg), doxepin's mechanism of action is dominated by potent and selective antagonism of the histamine H1 receptor. Doxepin has one of the highest affinities for the H1 receptor of any known compound (Ki approximately 0.17 nM), which means that even at very low plasma concentrations, it effectively blocks histaminergic wakefulness signaling. The histamine system is a key component of the ascending arousal pathway -- histaminergic neurons in the tuberomammillary nucleus of the hypothalamus fire during wakefulness and become quiescent during sleep. By blocking H1 receptors, ultra-low dose doxepin reduces this wake-promoting signal, particularly during the latter half of the night when endogenous histamine levels naturally begin to rise, which is why it is especially effective for sleep maintenance insomnia. At these low doses, doxepin has negligible affinity for muscarinic, adrenergic, and serotonergic receptors, which explains the absence of anticholinergic side effects (dry mouth, constipation, urinary retention) and cardiovascular effects that plague higher-dose TCA use. At antidepressant doses (75-300 mg), doxepin additionally inhibits reuptake of serotonin and norepinephrine and blocks muscarinic, alpha-1 adrenergic, and 5-HT2 receptors, producing a much broader and less selective pharmacological profile.